Investor Alert: Pediatrix Medical Group Surpasses Analyst Price Target
In recent trading, shares of Pediatrix Medical Group Inc (Symbol: MD) climbed above the average analyst 12-month target price of $16.07, currently priced at $17.23 per share. When a stock hits an analyst’s target price, the analyst faces two options: either downgrade the stock based on its current valuation or increase the target price. The choice may hinge on recent developments within the company that could justify a price increase.
Understanding Analyst Targets
There are seven analyst targets within the Zacks coverage universe for Pediatrix Medical Group Inc, which contribute to this average. While the collective view is informative, individual opinions vary. For instance, one analyst forecasts a price of $15.00, while another predicts a price as high as $18.00. The standard deviation among these targets is $1.426, indicating differing perspectives on the company’s future performance.
Investor Considerations
The average target price of $16.07 per share helps investors gauge market sentiment based on broader analyst insights rather than relying on a single opinion. With Pediatrix’s stock price exceeding this target, investors may want to evaluate their strategies: Is $16.07 merely a stepping stone to a higher target, or has the stock price risen too quickly, prompting a reassessment of investment positions? Below is a table displaying current analyst ratings for Pediatrix Medical Group Inc:
| Recent MD Analyst Ratings Breakdown | ||||
|---|---|---|---|---|
| » | Current | 1 Month Ago | 2 Months Ago | 3 Months Ago |
| Strong Buy ratings: | 3 | 3 | 3 | 2 |
| Buy ratings: | 0 | 0 | 0 | 0 |
| Hold ratings: | 5 | 5 | 5 | 5 |
| Sell ratings: | 0 | 0 | 0 | 0 |
| Strong Sell ratings: | 0 | 0 | 0 | 0 |
| Average rating: | 2.25 | 2.25 | 2.25 | 2.43 |
The average rating, ranging from 1 (Strong Buy) to 5 (Strong Sell), reflects the consensus of these analysts. Data for this report is sourced from Zacks Investment Research via Quandl.com. For more information, access the latest Zacks research report on MD — available for free.
Explore the Top 25 Broker Analyst Picks of the S&P 500 »
Additional Insights:
Funds Holding CTKH
VALE Stock Predictions
Institutional Holders of MVIN
The views and opinions expressed herein are those of the author and do not necessarily reflect those of Nasdaq, Inc.
